JP2020505322A5 - - Google Patents

Download PDF

Info

Publication number
JP2020505322A5
JP2020505322A5 JP2019531615A JP2019531615A JP2020505322A5 JP 2020505322 A5 JP2020505322 A5 JP 2020505322A5 JP 2019531615 A JP2019531615 A JP 2019531615A JP 2019531615 A JP2019531615 A JP 2019531615A JP 2020505322 A5 JP2020505322 A5 JP 2020505322A5
Authority
JP
Japan
Prior art keywords
patent document
international
prior
documents cited
international publication
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2019531615A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020505322A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2018/012579 external-priority patent/WO2018129313A1/en
Publication of JP2020505322A publication Critical patent/JP2020505322A/ja
Publication of JP2020505322A5 publication Critical patent/JP2020505322A5/ja
Pending legal-status Critical Current

Links

JP2019531615A 2017-01-06 2018-01-05 局所用デトミジン製剤 Pending JP2020505322A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762443174P 2017-01-06 2017-01-06
US62/443,174 2017-01-06
PCT/US2018/012579 WO2018129313A1 (en) 2017-01-06 2018-01-05 Topical detomidine formulations

Publications (2)

Publication Number Publication Date
JP2020505322A JP2020505322A (ja) 2020-02-20
JP2020505322A5 true JP2020505322A5 (enExample) 2021-01-14

Family

ID=61054537

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2019531615A Pending JP2020505322A (ja) 2017-01-06 2018-01-05 局所用デトミジン製剤

Country Status (15)

Country Link
US (2) US20190343805A1 (enExample)
EP (1) EP3565526B1 (enExample)
JP (1) JP2020505322A (enExample)
KR (1) KR20190110561A (enExample)
CN (1) CN110114059A (enExample)
AU (1) AU2018205217B2 (enExample)
BR (1) BR112019011961A2 (enExample)
CA (1) CA3049389A1 (enExample)
DK (1) DK3565526T3 (enExample)
ES (1) ES2982022T3 (enExample)
HU (1) HUE068070T2 (enExample)
IL (1) IL266448B2 (enExample)
MX (1) MX382949B (enExample)
PL (1) PL3565526T3 (enExample)
WO (1) WO2018129313A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020012415A2 (en) * 2018-07-11 2020-01-16 Clexio Biosciences Ltd. Topical detomidine formulations
WO2020016827A1 (en) * 2018-07-18 2020-01-23 Clexio Biosciences Ltd. Purified crystalline detomidine hydrochloride monohydrate, anhydrate and free base with low amounts of iso-detomidine and other impurities by recrystallisation in water
BR112021020962A2 (pt) 2019-05-01 2021-12-14 Clexio Biosciences Ltd Métodos de tratamento de prurido
US20220211672A1 (en) 2019-05-01 2022-07-07 Clexio Biosciences Ltd. Methods of treating pruritus

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10256774A1 (de) * 2002-12-05 2004-06-24 Lts Lohmann Therapie-Systeme Ag Transmucosale und transdermale Arzneimittel mit verbesserter Wirkstoffresorption
FI20041425A0 (fi) * 2004-11-05 2004-11-05 Orion Corp Transmukosaalinen veterinäärinen koostumus
WO2011127586A1 (en) * 2010-04-15 2011-10-20 The Royal Institution For The Advancement Of Learning / Mcgill University Topical treatments for pain
WO2013076160A1 (en) * 2011-11-21 2013-05-30 Université Libre de Bruxelles Sustained release formulations useful in the treatment of diseases
EP2803668A1 (en) * 2013-05-17 2014-11-19 Boehringer Ingelheim International Gmbh Novel (cyano-dimethyl-methyl)-isoxazoles and -[1,3,4]thiadiazoles
CA2921221A1 (en) * 2013-08-14 2015-02-19 The Board Of Trustees Of The Leland Stanford Junior University Compositions and methods for controlling pain
US20150057351A1 (en) * 2013-08-22 2015-02-26 Sucampo Ag Method for treating neuropathic pain

Similar Documents

Publication Publication Date Title
JP2019502892A5 (enExample)
JP2020505322A5 (enExample)
CN111655682A (zh) 一种高活性sting蛋白激动剂化合物
JP2020530380A5 (enExample)
EP4248973A3 (en) Pyridazinone compounds and uses thereof
JP2021504430A5 (enExample)
JP2021505241A5 (enExample)
CN110139865A (zh) Fgfr抑制剂
MX2025009986A (es) Metodos para preparar composiciones proteicas estables
CN112543755A (zh) 一类细胞坏死抑制剂及其制备方法和用途
EP3752486A4 (en) Heptamethine cyanines for use as fluorescent markers of the biliary and renal systems
JP2019516789A5 (enExample)
EA202091478A1 (ru) Антитела
MX2022003820A (es) Metodos de tratamiento para modificar la hermodinamica.
EA202092156A1 (ru) Модифицированные олигонуклеотиды и способы применения в лечении таупатий
CN113710671A (zh) 作为布鲁顿酪氨酸激酶抑制剂的环状分子
JP2020500643A5 (enExample)
JP2020512939A5 (enExample)
JP2021502362A5 (enExample)
JP2020523490A5 (enExample)
JP2020523165A5 (enExample)
MA55507A (fr) Macitentan destiné à être utilisé dans le traitement de l'hypertension portopulmonaire
JP2020107131A5 (enExample)
JP2019521402A5 (enExample)
CN115485276A (zh) 氘代akt激酶抑制剂